Buy Or Sell Opportunity • May 29
Now 20% undervalued Over the last 90 days, the stock has risen 9.6% to €1.39. The fair value is estimated to be €1.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 10% over the last 3 years. Earnings per share has declined by 52%. Buy Or Sell Opportunity • May 14
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at €1.29. The fair value is estimated to be €1.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 10.0% over the last 3 years. Earnings per share has declined by 52%. New Risk • May 12
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€19.4m market cap, or US$22.8m). Announcement • May 07
BIO-UV Group S.A., Annual General Meeting, Jun 12, 2026 BIO-UV Group S.A., Annual General Meeting, Jun 12, 2026. Location: 850 avenue louis medard, lunel France New Risk • Apr 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€16.9m market cap, or US$19.5m). Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €1.50, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 20x in the Machinery industry in Germany. Total loss to shareholders of 67% over the past three years. Announcement • May 10
BIO-UV Group S.A., Annual General Meeting, Jun 13, 2025 BIO-UV Group S.A., Annual General Meeting, Jun 13, 2025. Location: 850 avenue louis medard, lunel France Reported Earnings • May 05
Full year 2024 earnings released Full year 2024 results: Revenue: €39.2m (down 6.8% from FY 2023). Net income: €31.4k (down 75% from FY 2023). Profit margin: 0.1% (down from 0.3% in FY 2023). New Risk • Apr 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€24.2m market cap, or US$26.5m). New Risk • Apr 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€25.2m market cap, or US$27.4m). New Risk • Dec 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€21.9m market cap, or US$22.9m). Reported Earnings • Sep 26
First half 2024 earnings released: EPS: €0.037 (vs €0.11 in 1H 2023) First half 2024 results: EPS: €0.037 (down from €0.11 in 1H 2023). Revenue: €21.8m (down 9.1% from 1H 2023). Net income: €374.5k (down 69% from 1H 2023). Profit margin: 1.7% (down from 5.1% in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Announcement • May 25
BIO-UV Group S.A., Annual General Meeting, Jun 26, 2024 BIO-UV Group S.A., Annual General Meeting, Jun 26, 2024. Location: 850 avenue louis medard, lunel France New Risk • Apr 04
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€24.4m market cap, or US$26.5m). New Risk • Feb 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€29.4m market cap, or US$31.7m). Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to €3.07, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Machinery industry in Germany. Total loss to shareholders of 46% over the past three years. New Risk • Oct 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€27.0m market cap, or US$28.6m). New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (€27.7m market cap, or US$29.2m). Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €2.45, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 10x in the Machinery industry in Germany. Total loss to shareholders of 57% over the past three years. Upcoming Dividend • Sep 20
Upcoming dividend of €0.06 per share at 1.1% yield Eligible shareholders must have bought the stock before 27 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 16% but the company is paying out more than the cash it is generating. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (2.8%). Board Change • Nov 16
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Head of Financial Information, COO & Director Laurent-Emmanuel Migeon is the most experienced director on the board, commencing their role in 2018. Independent Director Sylvie Roussel was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Jul 29
BIO-UV Group S.A. Ordinary Shares to Be Deleted from OTC Equity BIO-UV Group S.A. Ordinary Shares France(FR) will be deleted from OTC Equity effective from July 29, 2022, due to Inactive Security. Reported Earnings • May 01
Full year 2021 earnings released: EPS: €0.068 (vs €0.068 in FY 2020) Full year 2021 results: EPS: €0.068 (vs €0.068 in FY 2020). Revenue: €34.6m (up 5.0% from FY 2020). Net income: €794.8k (up 36% from FY 2020). Profit margin: 2.3% (up from 1.8% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 55%, compared to a 9.9% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Head of Financial Information, COO & Director Laurent-Emmanuel Migeon is the most experienced director on the board, commencing their role in 2018. Independent Director Sylvie Roussel was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €3.97, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Machinery industry in Germany. Total loss to shareholders of 35% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.50 per share. Reported Earnings • Sep 26
First half 2021 earnings released: EPS €0.057 (vs €0.015 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €17.2m (up 23% from 1H 2020). Net income: €588.3k (up €713.0k from 1H 2020). Profit margin: 3.4% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Announcement • Jun 10
BIO-UV Group S.A. (ENXTPA:ALTUV) announces an Equity Buyback for 10% of its issued share capital, for €1 million. BIO-UV Group S.A. (ENXTPA:ALTUV) commences share repurchases on June 2, 2021, under the program mandated by the shareholders in the Extraordinary General Meeting held on May 28, 2021. As per the mandate, the company is authorized to repurchase €10 million worth of its shares, such that it does not hold more than 10% of its issued share capital at any time. The shares will be repurchased at a maximum price at €17 per share. Is New 90 Day High Low • Mar 05
New 90-day low: €5.74 The company is down 4.0% from its price of €5.96 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.52 per share. Is New 90 Day High Low • Dec 28
New 90-day high: €6.66 The company is up 6.0% from its price of €6.28 on 29 September 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.60 per share. Is New 90 Day High Low • Oct 24
New 90-day low: €5.70 The company is down 8.0% from its price of €6.22 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.39 per share. Announcement • Oct 06
BIO-UV Group S.A. has completed a Follow-on Equity Offering in the amount of €12.720757 million. BIO-UV Group S.A. has completed a Follow-on Equity Offering in the amount of €12.720757 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,193,234
Price\Range: €5.8
Transaction Features: Subsequent Direct Listing Is New 90 Day High Low • Oct 02
New 90-day low: €5.74 The company is down 7.0% from its price of €6.14 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.18 per share. Reported Earnings • Sep 26
First half earnings released Over the last 12 months the company has reported total losses of €433.5k, with losses widening by 283% from the prior year. Total revenue was €25.9m over the last 12 months, up 55% from the prior year.